| Summary of results B: Participants with local adverse events | ||||||
| Comparison | Studies | Participants |
NSAID (%) |
Placebo (%) |
RR (95% CI) |
NNH (95% CI) |
| All NSAIDs | 42 | 6740 | 4.3 | 4.6 | 0.98 (0.80 to 1.2) | Not calculated |
| Diclofenac | 15 | 3271 | 3.1 | 4.3 | 0.78 (0.56 to 1.1) | Not calculated |
| Ketoprofen | 8 | 852 | 11 | 9.5 | 1.2 (0.83 to 1.7) | Not calculated |
| Piroxicam | 3 | 522 | 2.3 | 5.4 | 0.42 (0.17 to 1.1) | Not calculated |
| Felbinac | 3 | 397 | 3.0 | 1.5 | 1.9 (0.49 to 7.5) | Not calculated |
| Indomethacin | 3 | 354 | 6.3 | 2.2 | 2.7 (0.91 to 7.7) | Not calculated |
| Ibuprofen | 3 | 321 | 10 | 4.3 | 2.3 (0.98 to 5.4) | Not calculated |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.